About CYTODEL INC
CytoDel is a preclinical stage biopharmaceutical company developing recombinant botulinum toxin (rBoT) derivatives for therapeutic delivery to the neuronal cytoplasm, with applications in biodefense, nervous system disorders, and chronic pain.
Development of recombinant botulinum toxin (rBoT) derivativesIntraneuronal drug delivery technologyCreation of antibody fusion proteins for targeting previously inaccessible neuronal targetsBiobetter BoNT with improved safety margin for large muscle treatmentBiodefense applications, including antidote development for botulinum neurotoxin
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| Federal contract award | Department of the Interior | $1.4M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to CYTODEL INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.